Exacerbation of immune thrombocytopenia following COVID-19 vaccination.
David J KuterPublished in: British journal of haematology (2021)
There is concern that COVID-19 vaccination may adversely affect immune thrombocytopenia (ITP) patients. Fifty-two consecutive chronic ITP patients were prospectively followed after COVID-19 vaccination. Fifteen percent had no worsening of clinical symptoms but no post-vaccination platelet count; 73% had no new symptoms and no significant platelet count decline. However, 12% had a median platelet count drop of 96% within 2-5 days post vaccination with new bleeding symptoms; after rescue therapy with corticosteroids +/- intravenous immunoglobulin (IVIG), platelets recovered to >30 × 109 /l a median three days later. ITP exacerbation occurred independently of remission status, concurrent ITP treatment, or vaccine type. Safety of a second vaccine dose needs careful assessment.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- ejection fraction
- chronic obstructive pulmonary disease
- newly diagnosed
- chronic kidney disease
- prognostic factors
- stem cells
- peripheral blood
- sleep quality
- rheumatoid arthritis
- radiation therapy
- systemic lupus erythematosus
- respiratory syndrome coronavirus
- extracorporeal membrane oxygenation
- cell therapy